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Objective: single stage seeding within the timeframe of a typical vascular operation has not been successful. One reason for
this is poor cell adherence to the graft lumen once exposed to pulsatile blood flow. In this study we have carried out
investigations with the use of two different fibronectin-based peptides, fibronectin-like engineered protein polymer (FEPP)
which contains multiple copies of arginine-glycine-aspartate (RGD) and fibronectin adhesion promoting peptide (FAPP) to
improve cell adherence.
Materials and Methods: FAPP and FEPP were coated onto native polyurethane and heparinised polyurethane grafts. The
grafts were then seeded for either 1 or 2 h with human umbilical vein endothelial cells (HUVEC). After the incubation
period the cells were washed off and cell retention was calculated. Cell metabolism was measured using Alamar Blue, and
confirmed with scanning electron microscopy (SEM).
Results: heparinised grafts coated with FEPP showed the best cell retention after both 1 and 2 h seeding (80+ 4% vs
81+ 3%). This graft had no significant difference in cell retention after both times whilst all the other grafts had better cell
retention after a 2 h seeding. The Alamar blue and SEM results confirmed cell viability and function for all graft types.
Conclusion: heparinised graft coated with FEPP allows significant cell retention after only 1 h of seeding and shows
promise for single stage seeding.
Key Words: Endothelial seeding; Tissue engineering; Human umbilical vein endothelial cells; Arginine-glycine-aspartate;
Heparin; Polyurethane; Prosthetic graft.
Introduction
Seeding of endothelial cells (EC) onto the lumen of
prosthetic bypass grafts aims to improve their
patency.1,2 Seeding is of two types, single and two
stage. Single stage seeding refers to EC extraction
and seeding all within the timeframe of a typical
bypass operation.3,4 This avoids the need for cell cul-
ture and reduces operative time. Two stage seeding
involves cell extraction typically from an autologous
vein, culture until adequate cell numbers are avail-
able, and seeding in a rotating device until confluence
is reached on the lumenal surface at which time the
graft is implanted. So far only two stage seeding has
been successful in large clinical trials in patients.5,6
However, in this approach the patient is required to
undergo two surgical procedures which means that
it is incompatible with revascularisation for critical
ischaemia, arguably those most in need of endothe-
lialised grafts. Furthermore, the use of cell culture is
hazardous as in 30% of patients cells are not suitable
for use due to infection and poor cellular proliferation.
Therefore, there is still a demand for single stage
seeding. One of the reasons for the failure of single
stage seeding is that cells are lost on exposure to pul-
satile blood flow due to their poor attachment to the
lumen of the polymeric graft.7 This may be improved
by the use of newer adhesive agents based on fibro-
nectin.7 We have recently shown that chemically bond-
ing arginine-glycine-aspartate (RGD) and heparin to
this graft lumen using spacer arms improves EC cell
retention and retains the bioactivity of each moiety.8
However, this technique is at present relatively expen-
sive. Therefore, we have been investigating new pro-
tein polymers that may enhance cell attachment and
retention but which are cheaper and easier to imple-
ment surgically. In this study we have investigated
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fibronectin adhesion promoting peptide (FAPP) and
fibronectin-like engineered protein polymer (FEPP).
FAPP is a sequence found in the carboxy-terminal
heparin-binding domain of fibronectin and is known
to possess a small charge. FEPP is a polymer that
incorporates thirteen identical copies of the ten
amino acid cell attachment epitope (containing RGD)
from human fibronectin interspersed between struc-
tural peptide sequences engineered to have a high
positive charge. It is widely known that positively
charged surfaces are more conducive to EC adhesion
and morphological maturation.9,10 Therefore, using
highly charged adhesive agents might show greater
promise.
FAPP and FEPP have not been assessed previously
for seeding of vascular bypass grafts. All the experi-
ments were conducted using a compliant poly
(carbonate-urea)urethane bypass graft (MyoLink)TM,
which shows great improvement in EC attachment
and retention and compliance compared to the com-
monly used expanded polytetrafluoroethylene (ePTFE)
graft.11,12 This graft is currently undergoing a multi-
centre clinical trial as a lower limb bypass graft and is
clinically used in haemodialysis access.
In this paper we have conducted seeding experi-
ments on the MyoLink graft with these adhesives
using human umbilical vein endothelial cells
(HUVEC). HUVEC were used, as they are a readily
available source of pure endothelial cells and allow us
to accurately assess cell retention after 1 or 2 h of
seeding.
Materials and Methods
Prosthetic bypass graft
The chemistry and manufacture of this graft has
been published earlier.13 We have developed a poly
(carbonate-urea)urethane graft with an engineered
honeycomb structure. This is specifically designed to
enhance cell retention and allows the maintenance of
compliance post in growth of perivascular tissue
through a mechanism of wall compression without
the need for external dilatation, like most earlier poly
(ether)- and poly(ester)-based soft segment polyur-
ethanes. The stability of this polymer has been
shown by in vitro and in vivo studies to be very high.13
Adhesion moieties
FAPP is a sequence found in the carboxy-
terminal heparin-binding domain of fibronectin
(Sigma-Aldrich, U.K.). FEPP is a polymer that incor-
porates multiple copies of the RGD attachment ligand
as present in human fibronectin (Sigma-Aldrich,
U.K.). The latter is interspersed between structural
peptide sequences engineered to produce a high posi-
tive charge.
Experimental groups
Experiments were divided into 6 groups, each group
was repeated 6 times.
Group 1: Native MyoLink graft (Myo)
Group 2: Heparinised MyoLink graft (Hep)
Group 3: Myo  FAPP
Group 4: Myo  FEPP
Group 5: Hep  FAPP
Group 6: Hep  FEPP
Solutions of FAPP and FEPP were made in phosphate
buffered saline. One end of the 20 cm graft pieces was
tied off, adhesive solutions were instilled into the graft
and then the other end of the graft was tied off. The
grafts were then incubated overnight at 37 C with the
adhesives. On the day of the experiments, cryovials
were prepared and lined with the grafts as per previ-
ously published protocol.14 HUVEC were cultured
and used at third passage. The cells were trypsinised
and resuspended in complete medium (Medium 199,
Glutamine, penicillin, streptomycin and 20% foetal
calf serum). The grafts were seeded at a density of
2 105 cells/cm2 which has been found to be most
effective in our previous work with RGD and incu-
bated for either 1 or 2 h.14 At the end of the incubation
period the vials were washed thrice with phosphate
buffered saline and the washed cells collected and
counted. Samples of grafts were removed for scanning
electron microscopy (SEM). The rest of the seeded
grafts were incubated with Alamar Blue to assess cell
viability and metabolism at 4 and 24 h.15
Basically, the AlamarBlueTM (Serotec Ltd., Kidlington,
Oxford) assay is a trademark redox assay that
measures cell proliferation, cytotoxicity and viability
by incorporating resazurin and resarufin as colori-
metric oxidation reduction indicators that change in
colour in response to chemical reduction resulting
from cell metabolism. Briefly Alamar Blue is added
to the complete culture medium at a ratio of 1:9 and
this is then added to graft pieces. At 4 and 24 h, 50 ml of
the medium is removed and absorbance is measured
at wavelengths of 570 and 630 nm using a Multiscan
MS spectrophotometer (Labsystem Multiskan MS,
Labsystem, Finland) with control being Alamar
Blue and complete medium. The results obtained are
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arbitrary units but this can be converted to percen-
tages by dividing the values obtained with the control.
In a further experiment based on the results of the
above, Hep FEPP coated grafts were seeded for 1 h
with HUVEC at 2 105 cells/cm2 and incubated at
37 C. At the end of the incubation period, the graft
was washed, 1 cm pieces were cut and cultured for
7 days to assess long-term EC viability on the FEPP
coated graft. At the end of the third and seventh days,
the grafts were removed, put in 24 well plates and
Alamar Blue added. At the end of 24 h the Alamar
viability assay was performed and the pieces of graft
also underwent SEM. Controls were similarly coated
but were unseeded.
Data analysis and statistical methods
All the results were analysed using the Graph pad
prism version 3.00 program using the Kruskal±Wallis
test and Dunn Multiple Comparison tests and
Unpaired t-test.
Results
The cell retention after 1 or 2 h incubation is sum-
marised in Table 1. All the grafts except Hep FEPP
showed significantly better cell retention after the 2 h
incubation period. After 1 h seeding time the
Hep FEPP seeded graft was significantly better
than Myo (p5 0.01) and Hep FAPP (p5 0.05).
After 2 h incubation the Hep FEPP was significantly
better than Myo (p5 0.05).
The Alamar Blue results are summarised in Tables 2
and 3 and showed that cell metabolism after the 24 h
Alamar test was better in the 2 h seeded groups except
with Hep FEPP where the 1 h seeded graft was
slightly better. Figure 1 shows HUVEC lining the
Hep FEPP grafts after 1 and 2 h seeding.
In the second experiment, Hep FEPP seeded graft
showed continuing cell metabolism up to 7 days after
seeding. The Alamar results showed significant
results 3 days (p5 0.0065) and 7 days (p5 0.0001)
after seeding. This was further confirmed on the
SEM, these being shown in Figure 2 at 0, 3 and 7 days.
Discussion
Single stage seeding remains the ultimate goal for vas-
cular surgeons. In this procedure, the patients' EC are
extracted and then seeded onto the bypass graft, which
is then implanted back into the patient. This avoids the
need for cell culture and reduces operative time over-
all. It is, however, the most technically demanding. To
date only two stage seeding has shown good long-term
results and has now moved forward towards a multi-
centre phase II clinical trial. Although this trial is likely
to confirm the results of phase I of the study, two stage
seeding will always be limited to specialised teaching
hospitals that have cell culture facilities. Its other main
drawback is that in upto 30% of patients cell culture
will fail and these patients will then undergo bypass
using an unseeded graft.
Two possible reasons exist for the poor results of
single stage seeding namely the source of the cell, and
the poor adherence of the chosen cells. The type of
Table 1. Cell retention after 1 and 2 h seeding.
Type of graft % Cell retention
after 1 h seeding
(mean sem)
% Cell retention
after 2 h seeding
(mean sem)
p value
Myo 43.7 4.9 63.6 3 0.0054
Hep 54 7.9 73.3 2.3 0.0363
MyoFAPP 56.4 2.7 73.4 5.2 0.0209
MyoFEPP 61.5 3.5 78.7 3.9 0.0068
Hep FAPP 42.8 7 71.2 2.9 0.0075
Hep FEPP 80.2 4.2 80.8 3.2 0.9119
Myo: MyoLink, FAPP: Fibronectin adhesion promoting peptide,
FEPP: Fibronectin engineered polymer protein, Hep: Heparinized
MyoLink.
Table 2. Alamar BlueTM cell viability after 4 h.
Type of graft 1 h seeded
(mean sem)
2 h seeded
(mean sem)
p value
Myo 108.6 2.8 107.3 4.4 0.7722
Hep 118.4 1.4 120.6 2.5 0.4516
Myo FAPP 120.2 13.1 125.8 11.6 0.5269
Myo FEPP 120.2 4.7 127.8 6.2 0.3586
Hep FAPP 103.7 4.7 109.3 4.1 0.4457
Hep FEPP 130.5 4.5 124.9 5.6 0.1409
Myo: MyoLink, FAPP: Fibronectin adhesion promoting peptide,
FEPP: Fibronectin engineered polymer protein, Hep: Heparinized
MyoLink. Results are given as a percentage compared to the control.
Table 3. Alamar BlueTM cell viability after 24 h incubation.
Type of graft 1 h seeded
(mean sem)
2 h seeded
(mean sem)
p value
Myo 171.5 6.8 259.9 20.6 0.0036
Hep 271.5 7.1 287.4 7.5 0.2557
Myo FAPP 240.7 35.9 258.9 20.4 0.6689
Myo FEPP 222 16 245.7 13 0.2909
Hep FAPP 219.8 7.5 236.2 6.8 0.2808
Hep FEPP 261.6 11.6 260.3 2.4 0.6271
Myo: MyoLink, FAPP: Fibronectin adhesion promoting peptide,
FEPP: Fibronectin engineered polymer protein, Hep: Heparinized
MyoLink. Results are given as a percentage compared to the control.
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cells extracted from fat (the most common source for
single stage seeding) are not composed solely of EC
but also of mixtures of fibroblasts and smooth muscle
cells (SMC).16 The purification of subpopulations of
cells extracted from adipose tissue (omental and
subcutaneous fat) is of considerable interest and is
currently the basis of further research at our unit and
many other institutions. We have also been looking at
alternative sources for single stage seeding including
EC derived from blood, bone marrow, mesothelial
cells extracted from peritoneal lavage, and stem cells.
In this paper we have looked at the key problem
with single stage seeding that is improving cell adher-
ence. A recent review by our research unit has shown
that of the commonly used substrates, Fibronectin
(FN) has possibly the best effect on cell retention but
RGD, collagen and, laminin have also shown good
results.7 Our research group has gone on to show
that chemically bonded heparin and RGD shows the
best cell attachment in comparison to all other pub-
lished studies but because this is relatively expensive
we have been looking at other cheaper polymers and
technique(s). It was our hypothesis in this study that a
polymer containing repeating sequences of RGD
would have the highest potential for cell attachment,
but in order to achieve a bonding to the surface we
postulated that surface charge was also required.
Myolink graft has a high negative surface charge;
thus, our hypothesis was that by adding a polymer
to the surface with a positive charge would result in a
charge transfer complex, a form of ionic bonding. It
was our further hypothesis that after EC adhesion to
the polymer surface and charge the positive charge
would disrupt and revert the surface back to a nega-
tive non-thrombogenic charge. To confirm our
hypothesis we therefore looked at FAPP and FEPP
both based on the fibronectin structure with surface
charges and with the ability to be easily coated
onto the graft surface and having the potential for
improving cell retention.
Fig. 1. Scanning electron microscopy of HepFEPP coated graft
showing extensive endothelial cell coverage after (a) 1 and (b) 2 h
seeding (all 283).
Fig. 2. Scanning electron microscopy showing endothelial cell cov-
ering graft at day (a) 0, (b) 3 and (c) 7 days after single stage seeding
(all times 220).
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Our results have shown that the best adhesive for
single stage seeding is a heparinised graft coated with
FEPP and they confirm our hypothesis that a combin-
ation of both charge and RGD type structure are most
effective. Because the results of this graft were not
significant after 1 or 2 h incubation, it can be used for
seeding after only 1 h incubation as compared to the
other grafts which had improved cell retention after
2 h incubation. The other advantage of using the
heparinised graft with FEPP is that heparin and RGD
are both antithrombogenic so that this may help pre-
vent early thrombosis of the graft.8 Further work is
underway currently using an atomic force microscope
force measuring technique in order to assess the
strength of the bond between the FEPP polymer and
poly(carbonate-urea)urethane surface. FAPP did not
show any significant advantage and this could be
due to not having any multiple sequences of RGD as
with FEPP. Interestingly the FEPP on a heparinised
graft shows a synergistic effect possible due to elec-
trostatic binding ± something we have seen in our
previous work.8 Our results are better than the previ-
ous work by Walluscheck and co-workers who only
used single sequences of RGD and where the RGD
coated ePTFE had a cell attachment of 30.6 2.1.17
This group had, however, only incubated the cells
for 30 min, which accounts for some of the differences
in their results compared to ours.
We conclude that for single stage seeding, a com-
bination of heparinised MyoLink graft coated with
FEPP provides excellent cell attachment and an anti-
thrombogenic surface. Furthermore due to the compli-
ant nature of the MyoLink graft, the combination of
enhanced anti-thrombogenicity with elastic properties
similar to native artery single stage seeding may
become a more realistic proposition. Further, in vivo
experiments with this graft seeded with EC extracted
from subcutaneous fat will be undertaken. However,
this will only be possible once we have developed a
reliable and reproducible technique for EC extraction
from subcutaneous fat which can be applicable at any
centre worldwide.
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